• Wondering if BeOne Medicines at around US$297.49 is still offering value after a strong run? This article focuses squarely on what that price might really represent.
• The stock has returned 23.1% over the past year. The shorter term picture shows a 0.2% slip over 7 days, 4.3% over 30 days and 4.4% year to date.
• Recent news around BeOne Medicines has kept attention on the stock, with investors weighing how company developments align with its current share price. These headlines help frame whether the recent 1 year gain sits comfortably with the fundamentals or raises fresh questions.
• On Simply Wall St's valuation checks, BeOne Medicines scores 3 out of 6. The next sections will break down what different valuation methods say about that score and then finish with a broader way to think about value that goes beyond the numbers alone.

Approach 1: BeOne Medicines Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return.

For BeOne Medicines, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $487.1 million. Analyst inputs are provided out to 2030, with projected Free Cash Flow of $2,681.9 million in that year, and Simply Wall St extrapolates beyond the explicit analyst period using its own growth assumptions.

Taking all projected cash flows and discounting them back to today results in an estimated intrinsic value of about $803.46 per share. Compared to the current share price of roughly $297.49, this DCF output indicates the stock is about 63.0% below this intrinsic value estimate based on these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BeOne Medicines is undervalued by 63.0%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: BeOne Medicines Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it links what you pay for the stock directly to the earnings the business is currently producing. It gives a quick sense of how many dollars investors are willing to pay for each dollar of profit.

What counts as a “normal” P/E often reflects how the market sees a company’s growth prospects and risk profile. Higher growth and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to justify a lower one.

BeOne Medicines currently trades on a P/E of 115.22x. That is well above the Biotechs industry average of 17.20x and also above the peer group average of 31.87x. Simply Wall St’s Fair Ratio for BeOne Medicines is 31.98x, which is its view of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and risk characteristics.

This Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for company specific features rather than assuming all Biotechs deserve the same multiple. Comparing 115.22x with the 31.98x Fair Ratio suggests the stock trades at a higher level than that Fair Ratio implies.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your BeOne Medicines Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of BeOne Medicines to a forecast and a fair value by turning your story about its products, risks and opportunities into explicit assumptions for future revenue, earnings and margins. You can then compare that Fair Value to the current share price while staying automatically updated as news and earnings arrive. For example, one investor might align with a more optimistic Fair Value near US$480, based on assumptions like 21.0% annual revenue growth, a 22.0% margin and earnings of US$2.1b by about April 2029. Another investor might prefer a more cautious Fair Value near US$336, built on 11.9% annual revenue growth, a 12.5% margin and earnings closer to US$937.4m. Both versions sit side by side within the Community page so you can quickly see which Narrative best fits your own expectations.

Do you think there's more to the story for BeOne Medicines? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.